List of Excipients in Branded Drug BRIVIACT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
UCB Inc	BRIVIACT	brivaracetam	50474-370	ANHYDROUS LACTOSE
UCB Inc	BRIVIACT	brivaracetam	50474-370	BETADEX
UCB Inc	BRIVIACT	brivaracetam	50474-370	CROSCARMELLOSE SODIUM
UCB Inc	BRIVIACT	brivaracetam	50474-370	LACTOSE MONOHYDRATE
UCB Inc	BRIVIACT	brivaracetam	50474-370	MAGNESIUM STEARATE
UCB Inc	BRIVIACT	brivaracetam	50474-370	POLYETHYLENE GLYCOL 3350
UCB Inc	BRIVIACT	brivaracetam	50474-370	POLYVINYL ALCOHOL

Briviact Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Briviact, the branded formulation of brivaracetam, has a relatively conventional excipient platform across its tablet, oral-solution, and injection presentations. The main commercial opportunities are generic substitution, excipient redesign for pediatric and geriatric patients, preservative-free or lower-allergen oral liquids, multiparticulate delivery, and manufacturing-cost reduction. The strongest barriers are bioequivalence, palatability, container-closure compatibility, controlled-substance handling, and any formulation-specific patent or regulatory exclusivity that remains enforceable.

What is Briviact and which dosage forms use excipients?

Briviact is indicated for the treatment of partial-onset seizures in patients aged one month and older. UCB markets brivaracetam in three primary dosage forms:

Dosage form	Marketed strengths or concentration	Primary commercial role
Film-coated tablets	10, 25, 50, 75, and 100 mg	Chronic outpatient maintenance therapy
Oral solution	10 mg/mL	Pediatric, geriatric, and swallowing-impaired patients
Injection	10 mg/mL	Short-term intravenous replacement when oral administration is temporarily impractical

The active ingredient is brivaracetam, a high-affinity synaptic vesicle protein 2A ligand. Excipients control powder flow, tablet compression, dissolution, taste, chemical stability, sterility, and administration convenience. The FDA-approved prescribing information identifies separate excipient systems for each presentation. (FDA, 2024a)

What excipients are used in Briviact tablets?

Briviact tablets use a conventional immediate-release formulation containing lactose, cellulose-based disintegrant and binder systems, lubricant, surfactant, and a film coat.

Briviact tablet excipient profile

The US tablet formulation includes:

• Lactose monohydrate
• Low-substituted hydroxypropyl cellulose
• Povidone
• Croscarmellose sodium
• Sodium lauryl sulfate
• Talc
• Magnesium stearate
• Polyvinyl alcohol in the film coating
• Titanium dioxide
• Polyethylene glycol
• Additional coating components, including talc

The formulation provides a relatively accessible target for generic manufacturers. Lactose is the principal diluent. Low-substituted hydroxypropyl cellulose and croscarmellose sodium support tablet breakup. Povidone contributes binding capacity, while magnesium stearate supports manufacturing ejection. Sodium lauryl sulfate can improve wetting and dissolution for a poorly or moderately water-soluble active pharmaceutical ingredient.

The commercial opportunity is not necessarily to reproduce every excipient. A generic manufacturer can use a qualitatively different and quantitatively different formulation if it meets applicable pharmaceutical equivalence, dissolution, stability, and bioequivalence requirements.

Which tablet excipients create generic-development risks?

The main risks are:

1. Lactose intolerance or excipient sensitivity claims in target patient populations.
2. Lubricant overuse, which can reduce dissolution.
3. Surfactant-level changes that alter wetting or gastrointestinal performance.
4. Differences in tablet hardness, friability, and disintegration.
5. Film-coat changes that affect swallowing and visual product identification.
6. Manufacturing variability across the five marketed strengths.

Because Briviact is available in multiple strengths, a manufacturer may need a strength-proportionality strategy. A single common blend can reduce validation and scale-up costs, but the approach must preserve dose uniformity and dissolution across the strength range.

What excipients are used in Briviact oral solution?

The oral solution uses an aqueous, sweetened, flavored, preserved system. The US label identifies:

• Sodium citrate dihydrate
• Citric acid monohydrate
• Methylparaben
• Sucralose
• Flavoring components
• Purified water

The citrate and citric acid system controls pH. Methylparaben provides antimicrobial preservation. Sucralose and flavoring address brivaracetam’s taste profile and improve adherence, particularly in children. The product is supplied at 10 mg/mL, which allows dose flexibility but also increases the importance of measuring-device accuracy and administration instructions. (FDA, 2024a; DailyMed, 2024)

What commercial opportunities exist in the oral solution?

The oral liquid is the highest-value excipient opportunity because patient acceptance depends on more than pharmacokinetic equivalence. Potential product concepts include:

• Preservative-free oral solution in unit-dose packaging
• Lower-sugar or sugar-free pediatric liquid
• Improved flavor systems with reduced bitterness
• Alcohol-free formulation where relevant to market requirements
• Ready-to-use oral suspension or reconstitutable powder
• Smaller-volume, higher-concentration presentation
• Premeasured oral syringes and adherence-oriented packaging
• Excipient systems designed for patients with dye, benzoate, or paraben concerns

Any reformulation must address chemical stability, microbial control, dose uniformity, taste masking, adsorption to dosing devices, extractables and leachables, and compatibility with high-density polyethylene or other container materials.

A higher concentration could reduce administration volume, but it may raise dosing-error risk. A lower concentration could improve pediatric titration but increase bottle size and excipient exposure. The optimal product depends on the target age band and reimbursement environment.

What excipients are used in Briviact injection?

Briviact injection contains:

• Sodium acetate trihydrate
• Glacial acetic acid
• Sodium chloride
• Water for injection

The acetate and acetic acid system supports pH control. Sodium chloride contributes isotonicity. The injection is supplied at 10 mg/mL and is intended for intravenous use when oral administration is temporarily unavailable. (FDA, 2024a)

What formulation barriers affect injectable competition?

Injectable competition faces higher technical and regulatory barriers than tablet competition. Development teams must demonstrate:

• Sterility and endotoxin control
• Particulate control
• Container-closure integrity
• Compatibility with infusion materials
• Stability during dilution and administration
• Absence of precipitation or adsorption
• Appropriate extractables and leachables profile
• Consistent pH and osmolality
• Low risk of injection-site irritation

Commercial opportunity exists for ready-to-administer presentations, premixed infusion bags, lower-waste vial sizes, and hospital-use packaging. The economics may be less attractive than tablets because sterile manufacturing, fill-finish, quality control, and hospital distribution add cost.

How strong is the Briviact excipient patent estate?

The excipient-related patent position should be separated from active-ingredient, formulation, method-of-use, and manufacturing patents.

Formulation patent exposure

A formulation patent may claim:

• Specific excipient combinations
• Concentration ranges
• pH ranges
• Stability characteristics
• Tablet dissolution profiles
• Oral-solution preservation systems
• Injectable compatibility or stability
• Specific dosage forms or administration methods

The presence of a listed Orange Book patent does not establish that every excipient substitution infringes. A generic sponsor typically evaluates claim scope, prosecution history, expiration, terminal disclaimers, and potential design-around routes. The relevant question is whether the proposed formulation practices a claim, not whether it resembles the commercial product.

The Briviact tablet excipient list itself does not establish patent protection. Many listed materials are standard pharmaceutical excipients available from multiple suppliers. Commercial defensibility is more likely to arise from the combination, concentration ranges, process conditions, stability data, or dosage-form architecture than from individual materials such as lactose, povidone, or magnesium stearate.

How should companies evaluate patent strength?

A practical formulation-patent review should score:

Factor	Higher-risk indicator
Claim breadth	Claims cover broad classes of binders, disintegrants, buffers, or preservatives
Design-around difficulty	Narrow pH, concentration, or dissolution ranges are commercially necessary
Remaining term	Patent expiration extends beyond expected ANDA approval
Orange Book status	Patent is listed for the relevant dosage form or method of use
Prosecution history	Applicant made narrowing amendments that may limit interpretation
Experimental support	Patent includes robust stability, bioequivalence, or dissolution data
Litigation history	Patent has survived a validity or infringement challenge

When does Briviact lose exclusivity?

Briviact’s US regulatory exclusivity has largely matured. FDA approval occurred in 2016, and five-year new chemical entity exclusivity would ordinarily have expired in 2021. Generic entry timing now depends primarily on patent status, ANDA review, Paragraph IV litigation, settlement terms, and regulatory approval.

The principal commercial distinction is between regulatory exclusivity and patent exclusivity:

Protection type	Briviact relevance
New chemical entity exclusivity	Five years from initial FDA approval, ordinarily ending in 2021
Orphan-drug exclusivity	Not the primary US approval framework for Briviact
Pediatric exclusivity	May extend listed patents or exclusivity by six months if granted
Formulation patents	Can delay or shape generic entry for specific presentations
Method-of-use patents	Can create carve-out or litigation issues
Patent term extension	Must be verified against the relevant approved product and patent records
Data exclusivity outside the US	Varies by jurisdiction

FDA Orange Book records and current patent certifications should control any launch analysis. (FDA, 2024b)

Which companies are challenging Briviact?

Generic competition is expected to come from ANDA applicants rather than biosimilar developers. Brivaracetam is a chemically synthesized small molecule, so biosimilar pathways do not apply.

Potential challengers may pursue:

• Tablet ANDAs
• Oral-solution ANDAs
• Injection ANDAs
• Paragraph III certifications with delayed entry
• Paragraph IV certifications challenging listed patents
• Section viii statements carving out patented methods of use

The identity and status of individual applicants, tentative approvals, litigation cases, and settlement agreements require review of current FDA ANDA records, Orange Book listings, and federal court dockets. A sponsor should not infer approval or launch timing from an unverified patent challenge.

What generic launch scenarios exist for Briviact?

Three launch scenarios are commercially relevant.

Early launch after successful patent challenge

A generic company may enter before all relevant patents expire if it prevails in litigation, obtains a favorable settlement, or establishes a noninfringing formulation and approved labeling. This scenario creates the greatest price pressure on Briviact tablets.

At-risk launch

An applicant may launch before final patent resolution. This can generate substantial damages exposure if the patent holder later prevails. At-risk entry is less likely where the branded product has meaningful hospital, pediatric, or specialty-market value.

Delayed launch after patent expiry or settlement

A settlement can define an agreed entry date, authorized-generic arrangement, or restrictions on specific dosage forms. The commercial effect depends on whether the agreement covers tablets only or also the oral solution and injection.

How does Briviact compare with competing antiseizure medicines?

Briviact competes with levetiracetam, lacosamide, lamotrigine, and other antiseizure medicines. Its excipient opportunity is strongest where the product can improve administration or tolerability rather than merely replicate a tablet.

Product characteristic	Briviact	Levetiracetam	Lacosamide
Active ingredient	Brivaracetam	Levetiracetam	Lacosamide
SV2A mechanism	Yes	Yes, lower-affinity interaction	No
Oral tablet	Yes	Yes	Yes
Oral liquid	Yes	Yes	Yes
IV presentation	Yes	Yes	Yes
Pediatric liquid opportunity	High	Established competition	Established competition
Excipient differentiation	Taste, preservation, dosing volume, packaging	Broad generic competition	Broad generic competition
Biosimilar relevance	None	None	None

Brivaracetam’s commercial differentiation depends more on clinical positioning, prescribing behavior, patient response, and supply reliability than on a unique excipient platform.

What manufacturing and supply-chain opportunities exist?

Excipient procurement can reduce cost and improve continuity, but supplier changes may trigger comparability work. Priority areas include:

• Dual sourcing for lactose, cellulose derivatives, povidone, and disintegrants
• Regional sourcing of preservatives and flavor systems
• Direct compression or simplified granulation
• Continuous manufacturing for tablets
• Lower-cost film-coat systems
• Reduced tablet weight without compromising handling
• Device-compatible oral-solution packaging
• Fill-finish optimization for injection
• Regional formulation adaptation for excipient restrictions

The oral solution has the greatest supply-chain sensitivity because flavor, preservative, container, and dosing-device changes can affect stability and patient acceptance. The injection has the highest operational risk because sterile manufacturing deviations can interrupt supply.

What FDA regulatory issues apply to Briviact excipient reformulation?

A generic tablet or oral solution generally must demonstrate pharmaceutical equivalence and bioequivalence under the applicable ANDA pathway. A materially different excipient system can require additional justification where it affects safety, tolerability, stability, dissolution, or bioequivalence.

Key FDA issues include:

• Inactive-ingredient safety at the proposed exposure
• Inactive Ingredient Database precedent
• Pediatric exposure to preservatives and sweeteners
• Flavor and color disclosure
• Oral-syringe dosing accuracy
• Stability through the proposed shelf life
• Comparative dissolution
• Container-closure compatibility
• Labeling consistency
• Sterility and particulate requirements for injection

A reformulated branded product may require a supplemental NDA or a new NDA strategy, depending on the nature of the change. A generic cannot assume that a clinically attractive excipient substitution will receive the same regulatory treatment as a routine manufacturing change.

What is the commercial value of Briviact excipient innovation?

The most credible opportunities rank as follows:

1. Pediatric oral solution with improved taste and dosing ergonomics.
2. Preservative-free or lower-exposure liquid for long-term use.
3. Higher-concentration liquid that reduces administration volume.
4. Tablet platform with lower manufacturing cost and equivalent dissolution.
5. Unit-dose or ready-to-use injectable packaging.
6. Modified-release or abuse-deterrent concepts, subject to clinical and regulatory feasibility.
7. Patient-specific multiparticulates for swallowing-impaired populations.

The strongest near-term business case is likely an oral-liquid or packaging improvement that supports adherence and reduces administration errors. A novel excipient alone is unlikely to create durable differentiation unless it produces measurable gains in stability, taste, dose accuracy, or manufacturing economics.

Key Takeaways

• Briviact has tablet, oral-solution, and injectable formulations, each with a different excipient strategy.
• Tablets use standard lactose, cellulose, povidone, disintegrant, surfactant, lubricant, and film-coat systems.
• The oral solution offers the clearest reformulation opportunity through taste, preservation, concentration, and dosing-device improvements.
• Injection competition faces greater sterile-manufacturing and compatibility barriers.
• Brivaracetam is a small molecule, so biosimilar risk does not apply.
• US NCE exclusivity ordinarily expired in 2021; current entry timing depends on patents, ANDA certifications, litigation, and settlements.
• Individual excipients are generally weak standalone differentiators. Combination claims, concentration ranges, stability, and process controls are more commercially relevant.
• A generic launch would likely pressure tablet pricing first, with oral-solution and injectable competition developing more slowly.
• Current Orange Book and court-docket verification is essential before making a launch or litigation decision.

FAQs

Can a generic Briviact manufacturer use different excipients?

Yes. A generic may use a different excipient system if the product satisfies pharmaceutical-equivalence, bioequivalence, quality, safety, dissolution, stability, and labeling requirements.

Is lactose in Briviact tablets a major market barrier?

Usually no. Lactose can be replaced or reduced in a generic formulation, but the substitute must preserve manufacturability, dose uniformity, dissolution, and stability.

Is the Briviact oral solution suitable for pediatric reformulation?

Yes. Pediatric reformulation opportunities include taste masking, lower administration volume, improved measuring devices, preservative reduction, and unit-dose packaging. Each change requires evaluation of stability, microbial control, and dosing accuracy.

Does Briviact have biosimilar competition?

No. Brivaracetam is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, not biosimilar approval pathways.

Which Briviact presentation is hardest to copy?

The injection is generally the most technically demanding because it requires sterile manufacturing, particulate control, container compatibility, and administration stability. The oral solution may present the greatest commercial differentiation challenge because taste and dosing usability are difficult to replicate by analytical testing alone.

References

1. DailyMed. (2024). BRIVIACT- brivaracetam tablet, film coated; BRIVIACT- brivaracetam solution; BRIVIACT- brivaracetam injection. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024a). BRIVIACT (brivaracetam) prescribing information. FDA. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

4. European Medicines Agency. (2024). Briviact: EPAR product information. EMA. https://www.ema.europa.eu/